Researchers have revealed an experimental weight-loss injection that helps remove accumulated fat under the skin, while also reducing visceral fat surrounding internal organs, which is linked to a higher risk of heart disease and diabetes.
Hot Topics
Robots enter US construction sites Will technology solve the housing crisis?
The drug, called "CBL-514," works through a mechanism that differs from popular weight loss drugs such as "Wegovi" and "Mongaro," as it directly targets fat cells and stimulates their destruction, rather than relying primarily on reducing appetite and promoting a feeling of satiety.
In a phase 2 clinical trial, approximately 70% of participants who received the drug experienced a significant reduction in subcutaneous fat during the treatment period. MRI measurements also showed a decrease in visceral fat in the participants who received the drug.
The study included 41 participants who received doses of up to 600 milligrams of CBL-514 or a placebo over three months. One month after the final dose, visceral fat levels in the group that received the drug decreased by approximately 12% compared to the start of the study, while they increased by approximately 6% in the placebo group.
Two months later, visceral fat levels remained about 10% lower in the drug group, while they increased by about 11.8% in the other group.
Dr. Timothy Garvey, one of the study's supervisors, said the results may have cosmetic benefits, such as reducing belly fat, but the greater health significance relates to reducing body weight and visceral fat, along with a possible improvement in indicators such as blood pressure and cholesterol.
The researchers also studied the use of CBL-514 with terzepatide, the active ingredient in Mongaro. In rat studies, the combination of the two drugs resulted in greater weight loss, and the animals regained less weight after discontinuing terzepatide.
Researchers believe the cause is the destruction of fat cells, which may reduce the body's ability to create and store fat again, but they emphasize that this effect requires further study. The side effects recorded in the trial were limited, consisting mainly of redness and pain at the injection site.
Despite the encouraging initial results, researchers stress the need for larger trials and longer follow-up periods to verify the drug's safety, effectiveness, and long-term impact.
Two phase 3 clinical trials are scheduled to begin to evaluate CBL-514 more broadly.
These findings come amid ongoing research to develop new weight-loss treatments and prevent weight regain after treatment is discontinued. Among these treatments is another experimental drug known as EloraTZP, which a 48-week study showed helped participants lose up to 23.3% of their body weight.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media